The research team led by Si, Mo, Zhao, and colleagues capitalized on the concept of microbubble-mediated drug delivery, an area rapidly gaining traction in medical sciences. Microbubbles, tiny gas-filled spheres traditionally used as contrast agents in ultrasound imaging, have emerged as versatile vehicles for targeted therapy. By conjugating these microbubbles with molecules that bind to E-selectin—a key cell adhesion molecule upregulated on inflamed renal endothelium—the researchers achieved highly selective delivery of therapeutic agents to sites of injury within the kidney microvasculature.

Cisplatin, an effective chemotherapeutic drug for various malignancies, unfortunately has nephrotoxicity as a significant dose-limiting side effect. It induces AKI primarily through oxidative stress, inflammation, and apoptosis of renal tubular cells. Current renoprotective strategies mainly involve hydration and dose reduction, which are often insufficient. Methylprednisolone, a potent corticosteroid with anti-inflammatory and immunosuppressive properties, has been recognized for its potential renal benefits. However, systemic administration limits its therapeutic index due to widespread side effects, prompting the need for targeted delivery systems to localize its action.

Utilizing E-selectin as a biomarker for inflamed endothelium provided the research team with a unique targeting mechanism. E-selectin is transiently expressed on activated endothelial cells during inflammation, playing a pivotal role in leukocyte rolling and adhesion, thus marking the loci of renal injury precisely. By loading methylprednisolone onto these engineered microbubbles, the scientists sought to increase drug concentration at the site of injury while minimizing systemic exposure and toxicity.

The utilization of ultrasound is a critical aspect of this therapeutic platform. Ultrasound waves can induce the cavitation of microbubbles, leading to their controlled rupture and localized drug release. This synergistic combination optimizes drug delivery in the microenvironment of the injured kidney, enhancing cellular uptake and therapeutic efficacy. Moreover, ultrasound itself aids in temporarily increasing vascular permeability, facilitating deeper penetration of the drug.

In experimental trials involving rats subjected to cisplatin-induced AKI, this novel therapeutic modality demonstrated remarkable efficacy. Compared to control groups receiving systemic methylprednisolone or untargeted microbubbles, rats treated with E-selectin-targeted microbubbles combined with ultrasound experienced significantly reduced renal inflammation, improved tubular epithelial survival, and lowered serum creatinine levels, a crucial marker of renal function.

Histopathological examinations revealed diminished infiltration of inflammatory cells and preservation of renal tubular morphology in treated animals. These findings were corroborated by molecular analyses showing downregulation of pro-inflammatory cytokines and markers of oxidative stress. Such multifaceted protection is indicative of the synergistic effects of targeted methylprednisolone delivery and ultrasound-mediated enhancement of bioavailability.

One of the most striking aspects of this study is the precise spatiotemporal control afforded by integrating ultrasound with microbubble technology. Unlike conventional drug administration, this approach allows clinicians to noninvasively orchestrate drug release exactly when and where it is needed. This precision reduces off-target effects and may allow for higher effective doses without increasing systemic toxicity, a major limitation encountered in current steroid therapies.

Beyond its immediate implications for AKI, this platform opens avenues for treating myriad renal pathologies characterized by endothelial inflammation and injury, such as glomerulonephritis, diabetic nephropathy, and ischemia-reperfusion injury. The adaptability of the microbubble surface for binding various ligands suggests potential customization for diverse targets and therapeutic agents, highlighting the versatility of this approach.

The study also addresses important safety considerations. The combined treatment did not show adverse effects on cardiovascular parameters or provoke excessive immune responses, reflecting the biocompatibility of the microbubbles and the specificity of targeting. This safety profile is fundamental for translational prospects, as it indicates tolerability in a systemic context.

Technically, the researchers achieved meticulous engineering of the microbubbles, optimizing size, shell composition, and ligand density to balance stability in circulation with efficient ultrasound-triggered release. Additionally, they calibrated ultrasound parameters to maximize therapeutic effects while minimizing tissue damage, underscoring the importance of interdisciplinary collaboration between bioengineers, pharmacologists, and clinicians.

While the study was conducted in animal models, it lays crucial groundwork for clinical trials. The ability to steer drugs to injured renal tissue noninvasively could address longstanding challenges in nephrology therapeutics, including the narrow therapeutic window and lack of targeted drug delivery options. Future investigations will need to establish scalability, dosing regimens, and long-term outcomes in human patients.

Interestingly, this technology might also lend itself to diagnostic applications. Given that E-selectin expression denotes active inflammation, such microbubbles could function as dynamic probes in ultrasound imaging to detect early kidney injury, enabling timely intervention. This theranostic duality exemplifies the cutting-edge nature of this research.

Overall, the convergence of targeted molecular recognition, nano-engineered delivery systems, and ultrasound technology embodied in this study represents a paradigm shift. It underscores how precision medicine principles can be actualized in renal disease management, moving beyond symptom control to sophisticated intervention at the cellular and molecular level. As contemporary medicine grapples with complex organ injuries, such innovative therapies exemplify the transformative potential of bioengineering advances.

In sum, the development of E-selectin-targeted microbubbles combined with ultrasound-induced drug release markedly enhances the renoprotective efficacy of methylprednisolone in cisplatin-induced acute kidney injury. This breakthrough in targeted delivery technology could redefine treatment modalities not only for AKI but also for a broad spectrum of inflammatory kidney diseases, portending a future where precision-directed therapeutics improve patient outcomes dramatically.

Subject of Research: Acute kidney injury; targeted drug delivery; E-selectin; microbubbles; ultrasound; methylprednisolone; cisplatin nephrotoxicity

Article Title: E-selectin-targeted microbubbles combined with ultrasound improves renoprotective effects of methylprednisolone on cisplatin-induced acute kidney injury in rats

Article References:
Si, R., Mo, L., Zhao, C. et al. E-selectin-targeted microbubbles combined with ultrasound improves renoprotective effects of methylprednisolone on cisplatin-induced acute kidney injury in rats. Sci Rep (2026). https://doi.org/10.1038/s41598-026-47547-x

Image Credits: AI Generated

The blood-brain barrier represents one of the foremost challenges in neurotherapeutics and brain disease management. This complex, selectively permeable membrane shields the brain’s delicate microenvironment from harmful agents such as toxins and pathogens, but at the cost of limiting access to potentially life-saving medications. Consequently, delivering chemotherapy agents or novel therapeutics to brain tissue in adequate concentrations has long been stymied by the BBB’s formidable protective function. Focused ultrasound, in conjunction with microbubble contrast agents, offers a non-invasive avenue to transiently and locally open this barrier, facilitating the controlled passage of drugs without compromising overall cerebral protection.

To rigorously characterize how focused ultrasound can enable this process with precision and reproducibility, Dr. Woodworth and his team conducted an extensive study involving 34 glioblastoma patients. These participants underwent up to six monthly cycles of treatment, culminating in an impressive dataset of 972 individual sonications—targeted ultrasound pulses aimed at specific brain regions. This large-scale effort allowed the team to meticulously analyze how different ultrasound parameters correlate with successful BBB disruption. Vital to this endeavor was the use of acoustic emissions monitoring: the capture of sound waves emitted by microbubbles oscillating in response to the ultrasound field, which serves as a real-time biomarker correlating with the degree of BBB opening.

Acoustic emissions, generated as microbubbles respond to the ultrasound energy, provide a novel, quantitative feedback mechanism enabling clinicians to fine-tune the treatment dose and target. As Dr. Woodworth explains, these signals allow for reliable prediction of BBB opening events, fostering safer and more effective therapeutic delivery. By correlating the acoustic signatures with MRI imaging and clinical outcomes, the team developed dosing guidelines that transcend individual device differences and patient variability, establishing a unifying framework for blood-brain barrier modulation through focused ultrasound across diverse clinical environments.

The study’s technical rigor is complemented by its translational importance. Previously, the lack of standardized protocols and monitoring impeded broader clinical adoption of ultrasound-mediated BBB opening. This research, therefore, marks an essential milestone, elucidating the spatial control and dosing strategies necessary for consistent, reproducible BBB disruption. Consequently, this advancement promises to accelerate the integration of ultrasound-facilitated drug delivery into routine neuro-oncological care, ultimately enhancing therapeutic efficacy for glioblastoma and potentially other neurological conditions.

The procedural basis for this treatment uses microbubbles—microscopic, inert gas-filled spheres introduced intravenously—which underlie the focused ultrasound technique. When exposed to low-intensity ultrasound waves, these microbubbles oscillate rhythmically within the cerebral vasculature. Their mechanical activity induces transient, microscopic disruptions in the tight junctions of the endothelial cells that compose the BBB, creating temporary pores through which therapeutic agents can pass. Crucially, this process is reversible and highly localized, minimizing off-target effects and preserving overall brain function while improving drug penetration.

Dr. Pavlos Anastasiadis, Assistant Professor of Neurosurgery at UMSOM and a co-author on the study, highlights the mechanistic underpinnings of this phenomenon. The oscillation of microbubbles within the ultrasound energy field leads to subtle mechanical perturbations of the blood vessel walls in the brain, enabling a safe and reversible opening of the BBB. These events can be monitored in real time using advanced imaging and acoustic emission technologies, allowing clinicians to control the extent and location of barrier disruption with unprecedented precision.

The lineage of this work extends back to seminal experiments in the early 1990s at Brigham and Women’s Hospital’s Focused Ultrasound Lab, where microbubbles were first explored as agents for BBB modulation. Building on these foundational discoveries, senior author Dr. Alexandra J. Golby, Director of Image-Guided Neurosurgery at Brigham and Women’s Hospital, emphasizes that the present study validates a clinically feasible approach to repeatedly open the BBB in glioblastoma patients ahead of chemotherapy cycles. This iterative opening holds promise to vastly improve therapeutic accumulation within tumors, potentially enhancing survival and quality of life.

Data from this investigation were derived from a subset of patients enrolled in ongoing clinical trials spearheaded by Dr. Woodworth. These trials are critically assessing the clinical impact of ultrasound-facilitated BBB opening for enhancing the delivery of standard-of-care chemotherapy in glioblastoma. The research team plans to publish detailed clinical outcomes from these broader trials imminently, promising further valuable insights into safety, efficacy, and patient benefit.

Dr. Taofeek K. Owonikoko, Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, noted the far-reaching implications of these findings for the field of neuro-oncology and beyond. The study’s data offer the first detailed technical description of acoustic emissions dosing, a cornerstone for clinical and regulatory progress in the adoption of focused ultrasound as a precision treatment modality. This work solidifies the foundation on which larger pivotal trials and multi-center studies can build.

One such major trial underway is LIBERATE (NCT05383872), a diagnostics-focused study in glioblastoma patients. Co-led by Dr. Woodworth, this trial leverages MRI-guided focused ultrasound to assess not only therapeutic delivery but also diagnostic enhancement capabilities, representing a frontier in personalized medicine for brain cancer. The consortium ReFOCUSED—encompassing over 20 research sites across North America—collaborates on these efforts, aiming to harness focused ultrasound technology to transform clinical outcomes in brain disease through improved drug delivery and imaging.

This research was generously supported by Insightec Inc., the manufacturer of the focused ultrasound devices utilized, along with funding from the Focused Ultrasound Foundation. Their combined support underscores the growing momentum behind ultrasound-enabled therapies, fostering innovation at the intersection of technology, engineering, and clinical neuroscience.

In summary, this detailed elucidation of acoustic emissions-guided dosing and spatial control of BBB opening ushers in a new era in neurotherapeutics. Through meticulous technical exploration, this research offers a blueprint for safely breaching the brain’s protective barrier on demand, thereby expanding the armamentarium against formidable brain cancers such as glioblastoma. As standardized protocols permeate clinical practice, focused ultrasound’s promise as a non-invasive, targeted, and controllable delivery mechanism nears clinical reality, unlocking potential not just in oncology but across the landscape of neurological diseases.

Subject of Research: Focused ultrasound-mediated blood-brain barrier opening for enhanced drug delivery in glioblastoma
Article Title: Acoustic emissions dose and spatial control of blood-brain barrier opening with focused ultrasound
News Publication Date: 25-Aug-2025
Web References:

• University of Maryland School of Medicine
• University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
• Clinical Trial LIBERATE (NCT05383872)
• Journal Device DOI
  Image Credits: University of Maryland School of Medicine
  Keywords: Blood brain barrier, Glioblastomas, Cancer